{
    "name": "nifurtimox",
    "comment": "Rx",
    "other_names": [
        "Lampit"
    ],
    "classes": [
        "Antiprotozoal Agents"
    ],
    "source": "https://reference.medscape.com/drug/lampit-nifurtimox-342663",
    "pregnancy": {
        "common": [
            "Based on animal studies, may cause fetal harm when administered to pregnant females",
            "Published postmarketing reports on use during pregnancy are insufficient to inform a drug-associated risk of birth defects and miscarriage",
            "Pregnancy test recommended before initiating treatment"
        ],
        "specific": [
            {
                "type": "Report drug exposure",
                "description": [
                    "If administered during pregnancy",
                    "If patient becomes pregnant during treatment or within 6 months following last dose ",
                    "Report exposure by calling 1-888-842-2937"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Administered orally during organogenesis was associated with reduced fetal body weights in mice, reduced maternal and fetal body weights in rats",
                    "Treatment with nifurtimox did not produce fetal toxicity and no nifurtimox-related fetal malformations were observed",
                    "Abortions, reduced maternal weight gain, and reduced numbers of live fetuses in rabbits when orally administered during organogenesis at doses approximately equal to the MRHD in rodents and 2-times the MRHD in rabbits",
                    "An increased incidence of a fetal skeletal malformation (fusion of caudal vertebral bodies) occurred in rabbits at nifurtimox doses ~0.2x the MRHD",
                    "Advise pregnant women of the potential risk to a fetus"
                ]
            },
            {
                "type": "Disease-associated maternal and/or embryo/fetal risk",
                "description": [
                    "Published data from studies on chronic Chagas disease during pregnancy are inconsistent ",
                    "Treatment of chronic Chagas disease during pregnancy is not recommended ",
                    "Acute symptomatic Chagas disease is rare in pregnant females; however, symptoms may be serious or life-threatening",
                    "If a pregnant female presents with acute symptomatic Chagas disease, evaluate the risks versus benefits of treatment to the mother and the fetus "
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 6 months after final dose",
                    "Males with female partners of reproductive potential: Use condoms during treatment and for 3 months after final dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "May impair fertility in males of reproductive potential",
                    "Effects were not reversible in 75% of animals at 11 weeks after dosing"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Published literature demonstrates that nifurtimox is present in human breast milk with an estimated infant daily dose of less than 15% of the recommended daily dose for pediatric patients with Chagas disease",
            "No adverse effects reported on the small number of infants who were breastfed by treated mothers ",
            "There is no information on the effects of nifurtimox on milk production",
            "Monitor infants for vomiting, rash, decreased appetite, pyrexia and irritability if exposed to drug"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to nifurtimox or any of the excipients",
                "Alcohol consumption during treatment "
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Genotoxicity has been demonstrated in humans, in vitro in several bacterial species and mammalian cell systems, and in vivo in rodents; a study in treated children with Chagas disease aged 7 months to 14 years demonstrated a 13-fold increase in chromosomal aberrations",
                "Carcinogenicity has been observed in mice and rats treated chronically with nitrofuran agents which are structurally similar to nifurtimoximilar data have not been reported; association with carcinogenicity is unknown ",
                "May cause fetal harm when administered to pregnant females ",
                "May worsen conditions in patients with history of brain injury, seizures, psychiatric disease, or serious behavioral alterations; closely monitor these patients and in patients who develop neurological disturbances or psychiatric drug reactions during treatment",
                "Cases of hypersensitivity reported; reaction may be induced by nifurtimox or an immune response triggered by Chagas disease during treatment; at first sign of serious hypersensitivity, discontinue treatment ",
                "Decreased appetite and weight loss were reported; patients can lose their appetite or experience nausea/vomiting which can result in weight loss; check body weight every 14 days and adjust dose accordingly",
                "Nitrofuran derivatives may precipitate acute attacks of porphyria; administer tablets under close medical supervision in patients with porphyria"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Alcohol",
                        "Alcohol consumption during treatment is contraindicated",
                        "Alcohol may increase the incidence and severity of undesirable effects similar to other nitrofurans and nitroheterocyclic compounds"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Vomiting",
            "percent": "14.6"
        },
        {
            "name": "Abdominal pain",
            "percent": "13.2"
        },
        {
            "name": "Headache",
            "percent": "12.8"
        },
        {
            "name": "Decreased appetite",
            "percent": "10.5"
        },
        {
            "name": "Nausea",
            "percent": "8.2"
        },
        {
            "name": "Pyrexia",
            "percent": "7.3"
        },
        {
            "name": "Rash",
            "percent": "5.5"
        },
        {
            "name": "Diarrhea",
            "percent": "4.6"
        },
        {
            "name": "Decreased weight",
            "percent": "2.7"
        },
        {
            "name": "Dizziness",
            "percent": "2.7"
        },
        {
            "name": "Anemia",
            "percent": "2.7"
        },
        {
            "name": "Urticaria",
            "percent": "2.3"
        },
        {
            "name": "Eosinophilia",
            "percent": "2.3"
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Tremor",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Anxiety",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including anaphylaxis",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "Drug reaction with eosinophilia and systemic symptoms",
            "percent": null
        },
        {
            "name": "DRESS",
            "percent": null
        },
        {
            "name": "Muscle weakness",
            "percent": null
        },
        {
            "name": "Amnesia",
            "percent": null
        },
        {
            "name": "Polyneuropathy",
            "percent": null
        },
        {
            "name": "Apathy",
            "percent": null
        },
        {
            "name": "Agitation",
            "percent": null
        },
        {
            "name": "Psychotic behavior",
            "percent": null
        },
        {
            "name": "Sleep disorder",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        }
    ]
}